Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial
Published Online: 2017-10-?
Journal: The Lancet Oncology•Publisher: Elsevier BV
Authors: Albert Oriol•Amy S Kimball•Anita Zahlten-Kumeli•Douglas Joshua•Hartmut Goldschmidt•Heinz Ludwig•Katja Weisel•Leonard Minuk•Meletios A Dimopoulos•Philippe Moreau•Robert Z Orlowski•Roman Hajek•Ruben Niesvizky•Shibao Feng•Thierry Facon•Vania Hungria•Wee-Joo Chng
